Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 4

Conditions

Multiple Myeloma 420Lymphoma, Large B-Cell, Diffuse 93Leukemia, Lymphocytic, Chronic, B-Cell 88Lymphoma, Follicular 79Recurrence 68Lymphoma 60Neoplasms, Plasma Cell 57Lymphoma, Mantle-Cell 56Lymphoma, B-Cell, Marginal Zone 47Lymphoma, Non-Hodgkin 46Leukemia, Myeloid, Acute 34Leukemia 32Lymphoma, B-Cell 24Neoplasms 23Myelodysplastic Syndromes 23Waldenstrom Macroglobulinemia 18Hodgkin Disease 18Smoldering Multiple Myeloma 17Lymphoma, T-Cell, Peripheral 16Burkitt Lymphoma 14Hematologic Diseases 13Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Prostatic Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Sezary Syndrome 10Mycosis Fungoides 10Lymphoma, Large-Cell, Anaplastic 9Leukemia, Myelomonocytic, Chronic 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

Magnetic Resonance Spectroscopy 6Dexamethasone 6Cyclophosphamide 6Blood Specimen Collection 6Prednisone 5Positron Emission Tomography Computed Tomography 4Mammography 4Lenalidomide 4Colonoscopy 4pembrolizumab 3Tomography, X-Ray Computed 3Surveys and Questionnaires 3Melphalan 3Exercise 3Biopsy 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3weifuchun 2obinutuzumab 2fluciclovine F-18 2daratumumab 2carfilzomib 2Preoperative Exercise 2Positron-Emission Tomography 2Methods 2Magnetic Resonance Imaging 2Injections 2Gemcitabine 2Educational Status 2Doxorubicin 2Cytarabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Disease × Lenalidomide × Clear all
NCT01093196 2024-11-07

Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients

Fondazione EMN Italy Onlus

Phase 3 Completed
660 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT02215980 2024-07-22

STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDS

Fondazione EMN Italy Onlus

Phase 3 Completed
210 enrolled
Plasma cell

Disease, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT01160107 2023-06-29

RP_MPR

Fondazione EMN Italy Onlus

Phase 2 Completed
46 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡